Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Stopped early · Phase 2

Conditions studied: Obesity

In brief

The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.

Key facts

Study ID

NCT00367783

Run by

Pfizer

People needed

100

Starts

2006-06-01

Expected to finish

2007-04-01

Last updated by the study team

2011-08-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• BMI of 30-40 kg/m2

You may not qualify if…

• Women of childbearing potential

Where it is running

• Pfizer Investigational Site — Ann Arbor, Michigan, United States
• Pfizer Investigational Site — Kalamazoo, Michigan, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Charlotte, North Carolina, United States
• Pfizer Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.